Trial Profile
A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs KD 018 (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- 29 Apr 2019 Status changed from suspended to completed.
- 28 Jul 2017 Status changed from recruiting to suspended.
- 13 Jun 2014 Planned number of patients changed from 54 to 165, Phase changed from IB/II to II and study included an additional placebo arm. Also, primary endpoints and study inclusion/exclusion criteria have been updated accordingly.